provide a brief explanation of the FI and express why caution needs to be exercised when interpreting FI.
The FI is a statistical summary of an RCT that utilizes 1:1 randomization and an outcome measure that can be categorized into two levels (e.g. 30-day mortality, yes or no). When a study reaches a statistically significant difference (and the sample size per group is fixed), one can show that the number of positive responses differs between the groups. Without loss of generality, assume that a study is comprised of a novel intervention and a control condition and that fewer events will be observed in the intervention group (i.e. the intervention provides a protective effect to the patients). Suppose that the study results suggest that the intervention is protective and that the result is statistically significant. Upon careful observation, it is noted that the number of events is reasonably small and that in absolute number there is not a large difference between the two study groups. One might naturally ask the question 'how would the results be interpreted if one of the non-events in the intervention group switched to being an event?' Would the RCT result reach the same statistical conclusion? What if two patients switched? What if three? Etc. Table 1 shows this general process in the context of a clinical trial with n ¼ 100/group. The original study would have response rates of 6% (6/100) and 17% (17/100) for the intervention and control, respectively. The FI is defined as the minimum number of reversals that need to occur for the result to be no longer statistically significant at the alpha ¼ 0.05 level of significance using Fisher's exact test. 2 In the context of the table, the FI would be estimated to be 2.
Should a study with an FI ¼ 2 be interpreted differently from a study with FI ¼ 50? One naturally would want to conclude that the study with the larger FI has a more robust finding, i.e. the results are less 'fragile' when the FI is larger. Statistically, this is true, but caution is needed, as will be illustrated with a series of in silico (simulation) studies. For brevity, we will consider only three possible response Table A shows the results of one simulated clinical trial in which 6% (6/100) of the intervention group and 17% (17/100) in the control group experienced a clinical event (e.g. 30-day mortality). This result would reach statistical significance using Fisher's exact test (P ¼ 0.0249). Tables B and C illustrate how the Fragility Index is estimated for this study. Table B subtracts one non-event and adds one event to the intervention's results while holding the control data constant. This results in a new table which remains statistically significant (P ¼ 0.0484). Table C repeats this process one more time; however, in this case, the test for differences in response rate using Fisher's exact is no longer statistically significant (P ¼ 0.0856). Therefore, the Fragility Index is 2.
The opinions expressed in this article are not necessarily those of the Editors of the European Heart Journal or of the European Society of Cardiology. † doi: 10.1093/eurheartj/ehw427. rates for the intervention (5, 10, and 15%) and hold the control response rate constant at 15%. Sample size calculations for 5% vs. 15% and 10% vs. 15% would suggest that 140 and 686 participants per group would be required to achieve 80% power at the alpha ¼ 0.05 level of significance (two-sided). Accordingly, we simulated 2000 study results for sample sizes ranging from 100 to 1000 per group. We calculated Fisher's exact P-value and FI for each simulated data study. Summaries of the simulated results were computed to examine the relationships between empirical power, FI, and P-values. Simulations and data analysis were conducted using R version 3.2.3.
5 Figure 1A plots the distribution of the observed response rates by sample size as verification for the simulation implementation. The simulated response rates align very well with the true values and, as expected, an increased sample size decreased the study to study variability in the estimated event rates (had a lower standard error). Figure 1B shows another expected result; the P-value decreases with larger sample sizes when the effect size is nonzero (i.e. when the true response rate is either 0.05 or 0.1) and remains constant when there is no effect (i.e. when the true response rate is 0.15, which matches the control group's response rate). For the largest effect considered (5% vs. 15%), the P-values Furthermore, a sample size of 1000/group represents $7 times the number of patients as would be recruited for the trial under normal design considerations (i.e. 80% power and alpha ¼ 0.05). For the smaller effect (10% vs. 15%), the differences are less pronounced since the sample size inflation only reached a factor of 1.46. Nonetheless, the pattern remains. Figure 1C shows the relationship of the FI to sample size. Note that the pattern of the results looks nearly identical to that observed by looking at the P-value, albeit in an inverse manner. In fact, if the log10 of the P-value is plotted against the FI (Figure 1D) , a strong inverse relationship is observed; Spearman's rho ¼ -0.94, P < 0.0001. If all P-values >0.05 (where all FI ¼ 0) are set equal to 0.051, just to indicate that all insignificance is the same as with FI ¼ 0, then this correlation becomes -0.99. There is mathematical rationale for why this is happening, but it can be explained more easily figuratively. Fisher's exact test compares an observed 2 Â 2 table with those that could be configured to be 'more extreme'. The P-value is the sum of the probability of observing 2 Â 2 tables that are as extreme or more extreme than that observed (i.e. a quantification of how extreme the observed trial results are relative to what could be observed by chance under the null condition of equal efficacy for the intervention and control conditions). In the context of a clinical trial, more extreme 2 Â 2 tables are those that have larger differences with respect to the response rates. Decreasing the differences in responses rates, as is done with the estimation of the FI, results in a quantification of how extreme the observed trial results are relative to the null condition (much like the P-value).
This simulation study, while simplistic, illustrates a key limitation of the FI-it is repackaging of the P-value for a clinical trial. As is widely accepted, P-values should not be interpreted as a measure of effect. 6 Thus, while it is conceptually interesting to investigate how sensitive a study's interpretation is relative to the number of observed events, particularly in the context of drop out and/or lost to follow-up, 7 one cannot use the FI as a measure of the strength of the effect. For example, Figure 1D shows that an FI in the range of 0-30 can be obtained from all three relative efficacy levels (no effect, 15% vs. 15%; small effect, 10% vs. 15%; large effect, 5% vs. 15% for the intervention relative to control). Larger FIs for a given effect can be obtained by simply allowing the sample size to increase ( Figure 1C) .
Randomized controlled trials operate with fixed resources (e.g. funding, patient populations, time). These studies are designed to balance the sample size with expected efficacy. In doing so, the FI is also minimized and results will necessarily hinge on fewer events. This is unavoidable, particularly in the context of clinical equipoise and finite resources. While we agree that the FI provides an easy to interpret summary of an RCT, one must be cautious not to rank order the robustness of the conclusions solely on the FI. A broader approach that encompasses estimated efficacy, study design, and mitigation of biases is recommended.
In the study of Docherty et al., 4 the median FI for 20 RCTs in heart failure was reported to be 26. Their conclusion that the results of these clinical trials hinge on a relatively small number of events is completely valid. The authors rightfully suggest that the FI must be coupled with other statistical summaries from the study. As our simulation studies illustrate, the FI is strongly associated with the P-value, and, as such, one must be careful to not conflate the FI with the strength of association in absence of the broader context of the study.
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